Background: Since antimicrobial resistance is a rising danger and a serious threat to the health of humans, recent studies have revealed that routine tests, such as minimum inhibitory concentration (MIC), are not enough to detect heteroresistance (HR) phenotype (i.e., phenotypic heterogeneity in antibiotic susceptibility in the identical bacterial population), and medical laboratories require awareness raising to face it. Colistin is regarded as the final therapeutic option for infections caused by carbapenem‐resistant gram‐negative bacteria. In this study, we explored the presence of HR to colistin in carbapenem‐resistant Pseudomonas aeruginosa isolates in Iran. Methods: From 2019 to 2020, 100 P. aeruginosa clinical isolates were gathered from hospitals in various regions in Iran. In the present study, antibiotic susceptibility testing was used to determine antibiotic resistance. The population analysis profile (PAP) test was conducted to measure HR. Additionally, PCR was carried out to detect metallo‐ β ‐lactamase genes, including blaNDM-1 and blaIMP , and blaVIM genes of colistin heteroresistant isolates. Results: As a result, of the 100 P. aeruginosa isolates that were tested by AST, 66 were resistant to carbapenem antibiotics. Here, we found that 62 carbapenem‐resistant Pseudomonas aeruginosa (CRPA) isolates were susceptible to colistin, while four isolates were resistant to colistin. Regarding the PAP assay, we identified eight heteroresistant isolates, of which three and two isolates carried blaNDM-1 and blaIMP genes, respectively. Furthermore, the HR isolates demonstrated a stable phenotype after seven subcultures in Mueller Hinton agar (MHA) without antibiotics. Conclusions: Finally, our study highlights the interplay between HR and its diagnosis methods. Since it is difficult to detect heteroresistant isolates by routine tests in clinical laboratories, it might be misclassified as susceptible and lead to challenges for clinicians and their patients.
Infantile hemangioma (IH) is a common benign tumor that occurs in children, affecting both blood vessels and soft tissues. Its pathological features includ
Transfusion therapy is crucial for treating Transfusion-dependent thalassemia (TDT) patients. However, the production of Alloantibodies presents a substantial challenge for these individuals and impacts their quality of life. The Rh and Kell blood group antigens are particularly susceptible to alloantibody development. This study aims to establish the correlation between HLA-DRB1*04, HLA-DQB1*03, and HLA-DQB1*06 alleles and alloimmunzation in thalassemia patients from Iran. 98 thalassemic patients were recruited for this study (49 alloimmunized and 49 non-alloimmunized). Alloimmunized patients developed Rh and Kell specificities alloantibodies. The two groups were compared based on the results of HLA-DRB1 and HLA-DQB1 genotyping conducted using Sequence-Specific Primers (SSP-PCR). The findings from the antibody screening revealed that the predominant alloantibody detected was Anti-K (95.9%), Anti-E (65.3%), Anti-C (30.6%), Anti-D (28.6%), Anti-c (10.2%), Anti-e (2%), and Anti-k (2%). There was a notable difference in HLA-DQB1*03 between alloimmunized and non-alloimmunized groups, 41.8% vs. 58.2%, respectively. (iP = 0.001, OR = 0.135, CI = 0.036–0.499). There was not any notable relationship between HLA-DRB1*04 and HLA-DQB1*06 alleles and alloimmunization. Our findings indicate that HLA-DQB1*03 may have a protective role in preventing alloantibody production. Thus, HLA-typing, particularly focusing on DQB1*03, can significantly enhance the screening process, leading to improved blood transfusion management, reduced rejection of hematopoietic stem cell transplantation, and minimized blood transfusion complications.
1 January 2026 in International Journal of Microbiology
β ‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β ‐lactamase enzymes. The proliferation of these enzymes represents a critical threat to global public health, compounding therapeutic challenges and escalating healthcare costs. As the efficacy of conventional treatments diminishes, reliance on last‐resort agents like carbapenems and colistin has increased, in turn accelerating resistance to these precious final‐line options. To address this escalating crisis, the strategic combination of β ‐lactam antibiotics with β ‐lactamase inhibitors (BLIs) has emerged as a vital therapeutic approach, restoring the activity of β ‐lactams by inactivating the resistance enzymes. Since the introduction of clavulanic acid, significant progress has been made in expanding the BLI arsenal. This review provides a comprehensive analysis of the current landscape of novel BLIs that have been approved or are in advanced clinical development, delving into their distinct mechanisms of action, spectra of activity against Ambler molecular classes (A, B, C, and D), and evolving clinical applications. While early inhibitors primarily targeted serine‐ β ‐lactamases (SBLs), recent advancements have introduced agents with expanded profiles, including those effective against some Class D carbapenemases. A paramount, ongoing challenge remains the development of effective inhibitors against metallo‐ β ‐lactamases (MBLs), though promising candidates like taniborbactam and xeruborbactam are now in clinical development. This review synthesizes the current knowledge on these innovative inhibitors, from recently approved combinations like ceftazidime/avibactam and cefepime/enmetazobactam to those in advanced clinical trials, and critically examines the associated therapeutic challenges, including the emergence of resistance. By integrating mechanistic insights with clinical perspectives, this article is aimed at informing the ongoing battle against antimicrobial resistance and guiding the future development of life‐saving therapeutic strategies.
Background: According to the World Health Organization 2024 bacterial priority pathogens list, carbapenem‐resistant Enterobacterales (CRE) were listed among the critical priority pathogens. Heteroresistance (i.e., a bacterial isolate that appears susceptible but harbors resistant subpopulations) represents a challenge in traditional laboratory testing, which may lead to treatment failure with colistin. This phenomenon has been studied in many bacteria, including K. pneumoniae . To our knowledge, this is the first report of colistin heteroresistance in K. pneumoniae isolates using population analysis profiles (PAPs) in Iran. Methods: Between 2019 and 2020, 100 K. pneumoniae isolates were collected from various samples of hospitalized patients in Iran. This study primarily determined antibiotic resistance by antimicrobial susceptibility testing. Thereafter, the prevalence of colistin heteroresistance in K. pneumoniae isolates was evaluated by the PAP test. Heteroresistant isolates were typed by multilocus sequence typing (MLST). Results: The MIC test showed that 79 (79%) of the 100 K. pneumoniae isolates were susceptible to colistin. Overall, 2/79 colistin‐susceptible isolates were classified as heteroresistant isolates by the PAP method, with a colistin MIC of 0.5 μ g/ml. Importantly, after 5 serial passaging on colistin‐free plates, there was no increase in the MIC of the colistin‐resistant subpopulations, showing that heteroresistance cases were unstable. MLST revealed that heteroresistant isolates belong to ST377 and ST15. Conclusions: In conclusion, the current study contributes to our understanding of the challenges posed by heteroresistant isolates in clinical laboratories. Since heteroresistant isolates may be misidentified as susceptible by standard tests, these findings raise concerns regarding the interpretation of colistin susceptibility results.